

Letter to the Editor



OPEN ACCESS

Received: Feb 1, 2024

Revised: Feb 27, 2024

Accepted: Apr 8, 2024

Published online: May 9, 2024

Correspondence to

Hinpetch Daungsupawong

Private Academic Consultant, Lak 52,
Phonhong 10000, Lao People's Democratic
Republic.

Email: hinpetchdaung@gmail.com

© 2024 The Korean Society of Lipid and
Atherosclerosis.

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>)
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

ORCID iDs

Hinpetch Daungsupawong
<https://orcid.org/0009-0002-5881-2709>
Viroj Wiwanitkit
<https://orcid.org/0000-0003-1039-3728>

Funding

None.

Conflict of Interest

The authors have no conflicts of interest to
declare.

Data Availability Statement

Data sharing is not applicable to this article
as no datasets were generated or analyzed
during the current study.

Author Contributions

Conceptualization: Daungsupawong
H, Wiwanitkit V; Formal analysis:
Daungsupawong H; Supervision: Wiwanitkit
V; Writing - original draft: Daungsupawong H;
Writing - review & editing: Daungsupawong H,
Wiwanitkit V.

<https://e-jla.org>

Letter by Hinpetch Daungsupawong Regarding Article, The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era

Hinpetch Daungsupawong ,¹ Viroj Wiwanitkit ²

¹Private Academic Consultant, Phonhong, Lao People's Democratic Republic

²Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Chennai, India

► See the letter “The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era” in volume 13 on page 21.

Dear editor, we would like to discuss on the publication “The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era.”¹ Because the coronavirus disease 2019 (COVID-19) vaccine has stopped the virus's transmission, fewer people have become seriously ill and have required hospitalization; thus, it has been crucial in containing the pandemic. However, COVID-19 is moving into an endemic phase as more people become vaccinated and recover from the virus. This indicates that, like seasonal influenza, the virus will be present but less severe and more consistently. Because of this, some people could think less of the COVID-19 vaccine and be reluctant to get vaccinated out of fear of negative side effects. But it's crucial to acknowledge that COVID-19 continues to be a serious public health issue. Significant morbidity and mortality are still experienced by high-risk populations, and the incidence rate of new infections is still substantial. Consequently, vaccination against COVID-19 is essential for safeguarding these susceptible individuals.

To improve vaccine recommendations in the ever-evolving COVID-19 endemic age, further study and surveillance are necessary. In addition to highlighting the significance of researching the role of COVID-19 vaccination in this new phase, this review offers suggestions for future research directions and themes. In summary, even if the COVID-19 vaccine has proven to be successful in containing the pandemic, its importance in the endemic period should not be underestimated. Ensuring the long-term control of COVID-19 will need sustained efforts to encourage immunization and modify methods in response to changing data.

REFERENCES

1. Kim KH. The role of COVID-19 vaccination for patients with atherosclerotic cardiovascular disease in the upcoming endemic era. J Lipid Atheroscler 2024;13:21-28. [PUBMED](#) | [CROSSREF](#)